Disturbances in calcium homeostasis can lead to abnormal tissue calcification, a feature of many diseases including macular degeneration, and certain cancers. Current clinical imaging techniques, such as radiography, fluoroscopy, CT, electron-beam tomography, intravascular ultrasound, and MRI, can detect larger calcifications but they lack the sensitivity to visualize microcalcifications below the millimeter scale. Many of these procedures may be invasive, costly, or poorly tolerated by patients. Fluorescent probes offer a promising alternative for highly sensitive, non-invasive detection; however, only a limited number of calcium-specific fluorophores currently exist.

This patented technology introduces a new class of fluorescent probes specifically engineered to detect early-stage and micro-scale calcium deposits. These probes consist of an organic fluorescent core, such as porphyrins, phthalocyanines, acridines, BODIPY, or xanthene derivatives, which are functionalized with covalently bound phosphonate groups. These phosphonate groups bind calcifications with high affinity. Upon binding, the probes exhibit a distinct change in fluorescence intensity, enabling accurate visualization and quantification of calcified structures. Experiments with mouse tissue show clear fluorescent labelling of calcified structures. Initial tests on cell cultures confirm cell permeability and specific binding to calcium. The technology is at an advanced preclinical stage of development with promising results for diagnostic applications.